论文部分内容阅读
目的通过对舒张性心力衰竭病人分别给予血管紧张素Ⅱ受体拮抗剂和β受体拮抗剂治疗,比较两者治疗前后血浆脑钠肽(BNP)结果及左室功能多项指标的变化,评估治疗效果。方法选择门诊及住院患者共60例,分为对照组(20例)、倍他乐克治疗组(20例)和缬沙坦治疗组(20例)。在常规治疗下,分别给予倍他乐克和缬沙坦治疗3个月,应用多普勒超声心动图检测每一个患者治疗前后左室功能的多项指标,并同时测定该患者血浆BNP的浓度,将所有资料进行统计分析。结果倍他乐克治疗组和缬沙坦治疗组的血浆BNP水平与对照组比较,差异有统计学意义(P<0.05),LAD、IVS和LVD与对照组差异有统计学意义(P<0.01)。倍他乐克治疗组和缬沙坦治疗组之间的血浆BNP水平及左室舒张功能参数差异无统计学意义。结论倍他乐克和缬沙坦都对DHF患者有良好的临床效果。从近期疗效来看,应用倍他乐克与缬沙坦治疗,两者的疗效差异无统计学意义。
Objective To investigate the changes of plasma brain natriuretic peptide (BNP) and left ventricular function before and after treatment in patients with diastolic heart failure treated with angiotensin Ⅱ receptor antagonist and β receptor antagonist. treatment effect. Methods A total of 60 outpatients and inpatients were selected and divided into control group (20 cases), metoprolol group (20 cases) and valsartan treatment group (20 cases). Under conventional treatment, metoprolol and valsartan were respectively given for 3 months. Doppler echocardiography was used to detect multiple indexes of left ventricular function in each patient before and after treatment. The plasma BNP concentration , All the data for statistical analysis. Results Compared with the control group, plasma BNP levels in the betatrexate-treated and valsartan-treated groups were significantly different (P <0.05), and there was significant difference between LAD, IVS and LVD in the control group (P <0.01) ). Plasma BNP levels and left ventricular diastolic function parameters were not significantly different between the Betaloc and Valsartan groups. Conclusion Both Betaloc and Valsartan have good clinical effect on patients with DHF. From the recent efficacy point of view, the application of metoprolol and valsartan treatment, the difference between the two was not statistically significant.